Inactive Instrument

Calendar Immunovant, Inc. Nasdaq

Equities

US45258J2015

Chart calendar Immunovant, Inc.

8c7ab20b8f86a3497.EHFgwX9y4_82C3I8iZ0bxv7vBDlYvvRavxJATA8a_nc.ITswjApHk7kbbCdlw-tXltOfcXsv-rkV5iojfmNAjjJTIQOlNgqZqBt_EQ~f905315a1160c9566f5a1a3b9bb96449

Upcoming events on Immunovant, Inc.

2024-06-30 Q4 2024 Earnings Release (Projected)
2024-08-06 Q1 2025 Earnings Release (Projected)
2024-10-31 Q2 2025 Earnings Release (Projected)
2025-02-11 Q3 2025 Earnings Release (Projected)

Past events on Immunovant, Inc.

2024-02-12 07:00 am Q3 2024 Earnings Release
2024-01-09 10:30 am JPMorgan Healthcare Conference
2023-11-30 11:30 am Piper Sandler Healthcare Conference
2023-11-28 05:05 pm Evercore ISI HealthCONx Conference
2023-11-28 08:00 am IMVT-1402 Phase 1 Results Call
2023-11-15 01:50 pm Stifel Healthcare Conference
2023-11-09 07:00 am Q2 2024 Earnings Release
2023-09-26 08:00 am IMVT-1402 Phase 1 Results Call
2023-08-21 04:30 pm Annual General Meeting
2023-08-10 07:00 am Q1 2024 Earnings Release
2023-05-22 07:00 am Q4 2023 Earnings Release
2023-02-03 07:00 am Q3 2023 Earnings Release
2022-11-14 03:55 pm Guggenheim Immunology and Neurology Day
2022-11-04 07:00 am Interim 2023 Earnings Release
2022-09-28 11:15 am Roivant Investor Day
2022-09-14 04:00 pm H.C. Wainwright Global Investment Conference
2022-09-07 08:00 am Business Update Call
2022-08-17 02:30 pm Annual General Meeting
2022-08-05 07:00 am Q1 2023 Earnings Release
2022-06-08 08:00 am FY 2022 Earnings Call

Annual results

Fiscal PeriodMarzo 2020 2021 2022 2023 2024
Net sales
Million USD
Released
Forecast
Spread
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-

0,00

EBITDA
Million USD
Released
Forecast
Spread
0,00
0,00
-
-108
-112
3.52%
-156
-135
-15.3%
-218
-186
-17.49%

-259

EBIT
Million USD
Released
Forecast
Spread
-66,1
-77,7
14.97%
-108
-113
3.94%
-156
-151
-3.48%
-218
-201
-8.6%

-266

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
-66,3
-65,5
-1.19%
-108
-112
4.01%
-157
-157
-0.06%
-211
-207
-1.82%

-252

Net income
Million USD
Released
Forecast
Spread
-66,4
-65,6
-1.24%
-107
-112
4.17%
-157
-156
-0.33%
-211
-205
-2.85%

-250

EPS
USD
Released
Forecast
Spread
-1,54
-1,15
-33.91%
-1,22
-1,29
5.34%
-1,43
-1,39
-2.75%
-1,71
-1,65
-3.72%

-1,79

Announcement Date29/06/2001/06/2108/06/2222/05/23-

Quarterly results

Fiscal PeriodMarzo 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales
Million USD
Released
Forecast
Spread
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-

0,00


0,00


0,00


0,00


0,00

EBITDA
Million USD
Released
Forecast
Spread



-47,2
-28,2
-67.54%
-40,3
-30,0
-34.53%
-49,6
-33,8
-46.65%
-64,0
-36,5
-75.47%
-64,2
-40,9
-57.15%
-78,4
-44,0
-78.24%
-61,7
-45,4
-35.95%
-61,4
-60,5
-1.55%

-57,7













EBIT
Million USD
Released
Forecast
Spread
-41,3
-36,8
-12.1%
-47,2
-42,6
-10.95%
-40,4
-46,2
12.64%
-49,6
-45,6
-8.81%
-64,0
-49,3
-29.97%
-64,3
-54,5
-17.84%
-78,5
-60,2
-30.37%
-61,8
-64,8
4.56%
-61,6
-64,1
4.02%

-64,7


-68,8


-73,1


-75,8


-78,5

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
-41,4
-36,0
-14.96%
-47,2
-44,8
-5.28%
-40,0
-46,1
13.15%
-47,7
-47,1
-1.11%
-62,8
-50,0
-25.62%
-60,4
-57,8
-4.59%
-73,9
-59,8
-23.73%
-58,2
-65,9
11.64%
-51,5
-65,4
21.2%

-65,2


-66,6


-68,4


-70,4


-76,4

Net income
Million USD
Released
Forecast
Spread
-41,4
-36,0
-14.96%
-47,2
-44,6
-5.65%
-40,4
-46,2
12.63%
-47,9
-46,3
-3.42%
-63,2
-50,8
-24.41%
-59,4
-57,8
-2.74%
-73,9
-57,3
-29.11%
-58,7
-62,9
6.72%
-51,4
-62,4
17.66%

-63,0


-65,3


-67,6


-70,3


-75,8

EPS
USD
Released
Forecast
Spread
-0,36
-0,32
-14.03%
-0,41
-0,36
-13.54%
-0,35
-0,40
11.55%
-0,41
-0,39
-6.41%
-0,49
-0,40
-23.02%
-0,46
-0,45
-1.36%
-0,57
-0,44
-28.48%
-0,45
-0,48
5.35%
-0,36
-0,43
16.71%

-0,44


-0,45


-0,46


-0,48


-0,51

Announcement Date04/02/2208/06/2205/08/2204/11/2203/02/2322/05/2310/08/2309/11/2312/02/24-----
  1. Stock Market
  2. Equities
  3. IMVT Stock
  4. Stock
  5. Calendar Immunovant, Inc.